8-K: bioAffinity Raises $1.8M in Direct Stock Offering
Registered Direct Offering
bioAffinity Technologies, Inc. completed a registered direct offering, raising approximately $1.8 million by selling 720,000 shares of common stock at $2.50 per share.
Summary
- bioAffinity Technologies, Inc. entered into a securities purchase agreement with institutional investors for a registered direct offering.
- The company issued 720,000 shares of common stock, par value $0.007 per share, at a purchase price of $2.50 per share.
- The offering closed on October 9, 2025, generating aggregate gross proceeds of approximately $1.8 million before deducting placement agent fees and other offering expenses.
- WallachBeth Capital, LLC acted as the exclusive placement agent, receiving an 8.0% cash fee of the aggregate gross proceeds and reimbursement of certain out-of-pocket expenses up to a maximum of $75,000.
- Net proceeds are intended for working capital, to support expected growing sales for CyPath Lung (its noninvasive test for lung cancer), and for general corporate purposes.
- Officers and directors of the company entered into lock-up agreements for a period of 60 days from the closing date, restricting the sale or transfer of company securities.
- The company agreed to restrictions on issuing common stock or common stock equivalents until November 14, 2025, and a prohibition on Variable Rate Transactions for six months following the closing date, with certain exceptions.
Sentiment
Score: 7
Explanation: The capital raise provides essential funding for the company's operations and growth initiatives, particularly for its key product, CyPath Lung. While there is dilution, securing capital is generally positive for a development-stage biotech company, indicating investor confidence and enabling continued progress.
Positives
- Secured approximately $1.8 million in gross proceeds, strengthening the company's financial position.
- Funds will be used for working capital and to support expected growing sales for CyPath Lung, a key product for early-stage lung cancer detection.
- The offering was priced at-the-market under Nasdaq rules, indicating market acceptance of the share price.
Negatives
- The issuance of 720,000 new shares of common stock will result in dilution for existing shareholders.
- Significant placement agent fees of 8.0% of gross proceeds, plus up to $75,000 in expenses, reduce the net proceeds available to the company.
- The company is subject to restrictions on future equity sales and variable rate transactions for specified periods, limiting financing flexibility.
Risks
- Forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations.
- Important factors that could cause actual results to differ materially from current expectations include general risk factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC.
Future Outlook
The company intends to use the net proceeds from the offering for working capital, to support expected growing sales for its noninvasive lung cancer test, CyPath Lung, and for general corporate purposes.
Management Comments
- The Company intends to use the net proceeds from the offering for working capital, to support expected growing sales for CyPath Lung, its noninvasive test for lung cancer, and general corporate purposes.
Industry Context
This capital raise provides crucial funding for a biotechnology company focused on noninvasive cancer detection, specifically for early-stage lung cancer with its product CyPath Lung. This aligns with broader industry trends towards less invasive diagnostic tools and continued investment in oncology research and development.
Comparison to Industry Standards
- NA The filing does not provide specific comparable companies, projects, or results for comparison to industry benchmarks. It details a capital raise transaction.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Lock-up Agreements | Officers and directors entered into lock-up agreements, agreeing not to offer, sell, transfer, or dispose of company securities for 60 days from the closing date, subject to exceptions. | 2025-10-09 | Aims to stabilize the stock price post-offering by preventing immediate sales by insiders. |
| Restrictions on Future Equity Issuances | Company agreed not to issue common stock or common stock equivalents until November 14, 2025, with certain exceptions. | 2025-10-08 | Limits the company's flexibility for additional capital raises or equity-based transactions in the short term, potentially protecting investors from immediate further dilution. |
| Prohibition on Variable Rate Transactions | Company agreed not to enter into agreements involving Variable Rate Transactions for six months following the closing date, with exceptions for at-the-market offerings and equity lines of credit expiring November 14, 2025. | 2025-10-08 | Protects investors from potentially highly dilutive financing structures where the price of shares issued varies with market trading prices. |
Legal Proceedings
- The company represents that there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to its knowledge, threatened against or affecting the company or any subsidiary that (i) adversely affects or challenges the legality, validity, or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect.
Related Party Transactions
- None explicitly disclosed in the provided filing or its exhibits, beyond standard compensation for officers and directors.
Stakeholder Impact
- Shareholders: Experience dilution from the issuance of new shares but benefit from strengthened working capital and funding for product growth and operations.
- Investors (Purchasers): Acquire shares at a fixed price, providing capital to the company.
- Employees: Benefit from the company's improved financial stability and ability to fund ongoing operations and product development.
- Customers: Potential for continued development and availability of CyPath Lung.
Next Steps
- Utilize net proceeds for working capital and general corporate purposes.
- Support and grow sales for CyPath Lung.
- Adhere to restrictions on future equity issuances and variable rate transactions for specified periods.
- Officers and directors will remain subject to a 60-day lock-up period.
Key Dates
| Date | Description |
|---|---|
| 2023-11-27 | Shelf registration statement on Form S-3 (File No. 333-275608) declared effective by the SEC. |
| 2025-10-08 | Company entered into a securities purchase agreement with institutional investors and a placement agency agreement with WallachBeth Capital, LLC. Press release announcing pricing of the offering issued. |
| 2025-10-09 | Offering closed. Press release announcing closing of the offering issued. |
| 2025-11-14 | Expiration of agreement not to issue common stock or common stock equivalents (subject to exceptions). Expiration of prohibition on at-the-market offerings and equity lines of credit. |
| 2025-12-08 | Approximate end of 60-day lock-up period for officers and directors (60 days from Closing Date of October 9, 2025). |
| 2026-01-30 | Expiration of Placement Agent's right of first refusal for future public and private equity, equity-linked, convertible, or debt offerings. |
| 2026-04-09 | Approximate end of six-month prohibition on Variable Rate Transactions and six-month period for Placement Agent's tail fee (six months from Closing Date of October 9, 2025). |
Recommendation
holdThe capital raise provides necessary funding for bioAffinity Technologies' operations and the growth of its CyPath Lung product. While the offering introduces dilution, it addresses immediate working capital needs and supports strategic initiatives. The restrictions on future equity sales and variable rate transactions offer some protection against further immediate dilution. However, without more comprehensive financial data and a deeper understanding of the company's long-term pipeline and market position, a stronger recommendation is not warranted. The current action is a necessary step for continued operations and growth, but investors should monitor the effective use of proceeds and future financial performance.
Keywords
bioAffinity Technologies, BIAF, Registered Direct Offering, Common Stock, Capital Raise, CyPath Lung, Biotechnology, Lung Cancer Detection, Noninvasive Test, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.